COVID-19中西医整合:动态循证临床实践指南

标题: COVID-19中西医整合:动态循证临床实践指南
title: Integrative Medicine for COVID-19: Living Evidence-based Practice Guideline
版本: 原创版
version: Original
分类: 标准指南
classification: Standard guideline
领域: 综合
field: Comprehensive guideline
国家和地区: 中国
Country and region: China
指南使用者: 该指南的目标用户包括发热门诊、急诊科、重症医学科、呼吸科和中西医结合治疗COVID-19患者或确诊患者的医务人员、公共卫生人员、科研工作者和社区居民。
Guide users: The target users of the guideline include medical personnel, public health personnel, scientific research workers and community residents in fever clinics, emergency departments, critical care medicine departments, respiratory departments, and integrative medicine who treat patients or diagnosed with COVID-19.
证据分级方法: 我们将使用推荐分级的评价、制订与评估 (GRADE) 工作组系统评估证据的确信度,并将证据分为高、中、低或非常低确信度。 随机对照试验的初始确信度为高,而观察性研究的初始确信度为低。 由于以下五个原因(偏倚风险、不精确性、不一致、间接性和发表偏倚),确信度被降级,并由于三个原因(影响幅度大、剂量反应梯度和可能的残余混杂的影响)而升级 )。 此外,在条件合适的情况下,还将考虑采用《中医药(中西医结合)临床实践指南制定与修订规范的证据质量分级和推荐》。
Evidence grading method: We will assess the certainty of evidence using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system and classify evidence as to be high, moderate, low, or very low certainty. The starting point for the certainty for RCTs is high, and for observational studies is low. The certainty will be downgraded due to the following five reasons (risk of bias, imprecision, inconsistency, indirectness, and publication bias) and upgraded due to three reasons (large magnitude of an effect, dose-response gradient, and effect of plausible residual confounding). Moreover, the Norms of development and revision for clinical practice guideline of Chinese medicine (Integrative medicine) Grading of evidence quality and recommendation will also be considered to use if the condition is appropriate.
制定单位: 兰州大学;中国中医科学院
Formulating unit: Lanzhou University; China Academy of Chinese Medical Sciences
注册时间: 2022-09-06
Registration time:
注册编号: PREPARE-2022CN583
Registration number:
指南制订的目的: 自 2019 年冠状病毒病(COVID-19)爆发以来,截至 2022 年 5 月 30 日,它已席卷 194 个国家,导致 5.25 亿例确诊病例和 628 万例死亡。在 COVID-19 流行期间,它对全球人口的身心健康、国际经济和贸易发展产生了重大影响。 西医在治疗COVID-19时采用了多种方法,如特异性药物、抗病毒药物、血浆疗法等。还有氧疗和呼吸机治疗,可以为患者提供生命支持,有效控制和降低死亡率.作为传统医学和补充医学的一部分,中医药是预防和控制中国 COVID-19 流行的重要因素。截至 2022 年 5 月 30 日,L-OVE COVID-19 存储库已包含 633 项关于 TCM10 的主要研究。根据世卫组织关于中医治疗 COVID-19 的评估报告,中医对 COVID-19 有效,尤其是对轻度和中度病例。面对疫情的严重发展,各国制定了临床实践指南(CPGs),为COVID-19的治疗提供指导。截至 2020 年 12 月 31 日,全球共发布了 92 篇 CPG,其中具有代表性且不断更新的 CPG 为世界卫生组织(WHO)发布的 《living guideline on drug for COVID-19》(第 10 版)和中国国家卫生健康委员会发布的《新型冠状病毒诊疗方案(第九版)》。除了现有CPG的整体质量较差外,CPG还存在以下问题。一是从临床应用来看,中医药的参与率达到90%以上,中西医混合使用。然而,大多数 CPGs 只是简单地推荐中医或 西医,因此这些 CPGs 不再符合临床实践。虽然有些CPG是中西医结合的,但也有单独推荐,具体用什么治疗也不清楚。二是没有根据疾病发展的全过程提出建议,没有很好地应用于患者或医生。 中医强调整体观和辨证论治,而西医强调还原论,注重辨病辨症。因此,坚持中西医整合,而不是中西医结合,最终可以通过将公认的证据转化为推荐来制定整合指南。整合值得信赖的指南将最先进的知识和技术融入临床实践,并在事实和经验医学条件下进一步实践整合。 整合指南以整合医学的核心理念为基础,通过各种因素的共同作用,相互融合,形成人类健康维护和疾病诊疗的最佳状态和方案。 因此,有必要制定符合国际标准的针对COVID-19的高质量整合动态循证指南,以提高治疗效果和患者的生活质量。 HIM指南采用活体系统评价的方法全面比较中西医疗效差异,遵循“依中则中,宜西则西“”的治疗原则,针对新冠肺炎的诊断、预防、治疗和康复提出建议。
Purpose of the guideline: Since the outbreak of the coronavirus disease 2019 (COVID-19), as of May 30, 2022, it has swept through 194 countries, resulting in 525 million confirmed cases and 6.28 million deaths. During the COVID-19 epidemic, it has had a major impact on the physical and mental health of the global population, international economic and trade development. WM used a variety of methods in the treatment of COVID-19, such as specific drugs, antiviral drugs, plasma therapy, etc. There were also oxygen therapy and ventilator treatment, which could provide patients with life support, and effectively control and reduce mortality. As a part of traditional and complementary medicine, Traditional Chinese medicine (TCM) was an important factor in preventing and controlling the COVID-19 epidemic in China. As of May 30, 2022, the L-OVE COVID-19 Repository had included 633 primary studies on TCM10. According to the WHO Report on the evaluation of TCM in the treatment of COVID-19, TCM were effectively treat COVID-19, especially for mild and moderate cases. In the face of the severe development of the epidemic, countries have developed CPGs to provide guidance on the treatment of COVID-19. As of December 31, 2020, a total of 92 CPGs have been published worldwide, of which the specific representative and continuously updated CPGs were the World Health Organization (WHO) published a living guideline on drug for COVID-19(10th edition) and the Guidance for Corona Virus Disease 2019 Prevention, Control, Diagnosis and Management (ninth edition) issued by China's National Health Commission (NHC). In addition to the poor overall quality of existing CPGs, CPGs had the following problems. First, from the perspective of clinical application, the participation of TCM has reached more than 90%, and the use of TCM and WM was mixed. However, most of the CPGs simply recommended TCM or WM, so these CPGs were no longer in line with clinical practice. Although some CPGs were combined TCM and W M, they were also recommended independently, and not clear what treatment should be used. Second, the recommendations were not made according to the whole process of disease development, and it was not well applied to patients or doctors. TCM emphasizes the holistic perspective and treatment based on syndrome differentiation, whereas WM emphasizes reductionism, focusing on recognizing diseases, identifying causes, and developing countermeasures. Therefore, adhering to the holistic integration of TCM and WM instead of the combination of TCM and WM, HIM guideline can be developed eventually by transforming recognized evidence into recommendations. Then the trustworthy guideline of HIM will integrate the most advanced knowledge and technologies in to clinical practice, and further practice HIM in the factual and empirical medicine conditions. Based on the key conceptions of holistic integrative medicine (HIM), the HIM guideline could develop the best state and program for human health maintenance and disease diagnosis and treatment through the joint action of various factors, and mutual integration. Therefore, it was necessary to develop a high-quality living evidence-based guideline of HIM for COVID-19 in line with international standards, to improve the treatment effect and patients' quality of life. The HIM guideline adopted the method of living systematic review to comprehensively compare the difference in the efficacy of TCM and WM, followed the treatment principle “if the curative effect of TCM was better, choose TCM, and vice versa”, and made recommendations focused on the diagnosis, prevention, treatment, and rehabilitation of COVID-19 according to the disease course.